| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mitochondria | 31 | 2023 | 487 | 4.070 |
Why?
|
| HIV Infections | 45 | 2023 | 2303 | 3.200 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 11 | 2019 | 31 | 3.170 |
Why?
|
| DNA, Mitochondrial | 27 | 2023 | 175 | 3.000 |
Why?
|
| Anti-HIV Agents | 17 | 2022 | 420 | 2.650 |
Why?
|
| Leukocytes, Mononuclear | 16 | 2024 | 234 | 2.250 |
Why?
|
| Adipose Tissue | 9 | 2019 | 177 | 2.000 |
Why?
|
| Reverse Transcriptase Inhibitors | 10 | 2019 | 57 | 1.690 |
Why?
|
| Insulin Resistance | 7 | 2022 | 184 | 1.550 |
Why?
|
| Adenine | 5 | 2012 | 44 | 0.890 |
Why?
|
| Zidovudine | 10 | 2022 | 34 | 0.890 |
Why?
|
| HIV-1 | 10 | 2020 | 706 | 0.790 |
Why?
|
| Adipocytes | 2 | 2019 | 58 | 0.770 |
Why?
|
| Cholesterol | 2 | 2020 | 205 | 0.760 |
Why?
|
| Adenosine Triphosphate | 3 | 2024 | 196 | 0.750 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2013 | 221 | 0.690 |
Why?
|
| Maternal-Fetal Exchange | 5 | 2011 | 29 | 0.690 |
Why?
|
| Monocytes | 4 | 2016 | 257 | 0.660 |
Why?
|
| Stavudine | 6 | 2015 | 13 | 0.650 |
Why?
|
| Humans | 63 | 2024 | 37093 | 0.620 |
Why?
|
| Female | 50 | 2022 | 20969 | 0.620 |
Why?
|
| Male | 46 | 2021 | 20025 | 0.610 |
Why?
|
| Inflammation | 5 | 2017 | 618 | 0.590 |
Why?
|
| Mitochondria, Heart | 7 | 2016 | 66 | 0.570 |
Why?
|
| Mitochondrial Diseases | 3 | 2021 | 16 | 0.570 |
Why?
|
| Oxidative Phosphorylation | 9 | 2020 | 53 | 0.560 |
Why?
|
| Adult | 28 | 2021 | 11712 | 0.500 |
Why?
|
| Anti-Retroviral Agents | 7 | 2022 | 147 | 0.490 |
Why?
|
| Lamivudine | 5 | 2012 | 20 | 0.480 |
Why?
|
| Mitochondria, Liver | 3 | 2001 | 17 | 0.450 |
Why?
|
| Cross-Sectional Studies | 14 | 2021 | 2721 | 0.440 |
Why?
|
| Middle Aged | 26 | 2020 | 10129 | 0.430 |
Why?
|
| Peripheral Nervous System Diseases | 5 | 2015 | 28 | 0.410 |
Why?
|
| Uridine | 1 | 2011 | 6 | 0.410 |
Why?
|
| RNA | 3 | 2011 | 241 | 0.390 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2011 | 103 | 0.390 |
Why?
|
| Nucleosides | 1 | 2011 | 30 | 0.370 |
Why?
|
| Cohort Studies | 7 | 2020 | 1492 | 0.370 |
Why?
|
| Macrophages | 1 | 2014 | 439 | 0.360 |
Why?
|
| Subcutaneous Fat | 3 | 2019 | 15 | 0.340 |
Why?
|
| Metformin | 2 | 2020 | 65 | 0.340 |
Why?
|
| Acetylcarnitine | 2 | 2009 | 8 | 0.340 |
Why?
|
| Pregnancy | 11 | 2022 | 1549 | 0.330 |
Why?
|
| Endodeoxyribonucleases | 2 | 2002 | 29 | 0.330 |
Why?
|
| HIV Seropositivity | 2 | 2012 | 190 | 0.310 |
Why?
|
| Cell Respiration | 3 | 2017 | 35 | 0.310 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 357 | 0.300 |
Why?
|
| Electron Transport Complex IV | 6 | 2019 | 37 | 0.290 |
Why?
|
| CD4 Lymphocyte Count | 8 | 2020 | 189 | 0.290 |
Why?
|
| Pilot Projects | 6 | 2020 | 661 | 0.280 |
Why?
|
| Skin | 3 | 2015 | 174 | 0.280 |
Why?
|
| Adiponectin | 2 | 2019 | 55 | 0.270 |
Why?
|
| Population | 1 | 2005 | 10 | 0.270 |
Why?
|
| HIV Seronegativity | 2 | 2005 | 39 | 0.260 |
Why?
|
| Cognition | 2 | 2020 | 398 | 0.260 |
Why?
|
| Mitochondria, Muscle | 2 | 2001 | 16 | 0.250 |
Why?
|
| Blood Coagulation Disorders | 2 | 2016 | 6 | 0.250 |
Why?
|
| Nerve Fibers | 4 | 2014 | 34 | 0.240 |
Why?
|
| Muscle, Skeletal | 3 | 2004 | 282 | 0.240 |
Why?
|
| Schools, Medical | 2 | 2018 | 198 | 0.240 |
Why?
|
| Mitochondrial Proteins | 2 | 2019 | 107 | 0.240 |
Why?
|
| Viral Load | 5 | 2019 | 312 | 0.240 |
Why?
|
| Case-Control Studies | 5 | 2020 | 1130 | 0.240 |
Why?
|
| Fetus | 1 | 2004 | 105 | 0.230 |
Why?
|
| Oxidative Stress | 5 | 2019 | 938 | 0.220 |
Why?
|
| Deoxyguanosine | 2 | 2016 | 35 | 0.220 |
Why?
|
| Adolescent | 8 | 2021 | 5363 | 0.220 |
Why?
|
| Erythrocebus patas | 5 | 2004 | 5 | 0.220 |
Why?
|
| Ritonavir | 3 | 2012 | 14 | 0.220 |
Why?
|
| Genome, Viral | 1 | 2023 | 109 | 0.210 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2022 | 6 | 0.210 |
Why?
|
| Neuroblastoma | 1 | 2023 | 129 | 0.210 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 3 | 2017 | 13 | 0.210 |
Why?
|
| Immunity, Innate | 1 | 2023 | 149 | 0.210 |
Why?
|
| Child | 6 | 2021 | 3131 | 0.210 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2021 | 2 | 0.210 |
Why?
|
| Selenoproteins | 2 | 2022 | 159 | 0.210 |
Why?
|
| Fibroblast Growth Factors | 1 | 2021 | 33 | 0.200 |
Why?
|
| Sensory Receptor Cells | 2 | 2015 | 32 | 0.200 |
Why?
|
| Interleukin-6 | 3 | 2017 | 153 | 0.200 |
Why?
|
| Brain | 5 | 2019 | 1346 | 0.190 |
Why?
|
| Cisplatin | 1 | 2001 | 72 | 0.190 |
Why?
|
| Ethanolamine | 1 | 2021 | 8 | 0.190 |
Why?
|
| Diabetes, Gestational | 1 | 2021 | 47 | 0.190 |
Why?
|
| Mitochondrial Myopathies | 1 | 2000 | 1 | 0.190 |
Why?
|
| Fetal Heart | 1 | 2000 | 4 | 0.180 |
Why?
|
| Veterans | 3 | 2017 | 122 | 0.180 |
Why?
|
| Aged | 8 | 2019 | 6741 | 0.180 |
Why?
|
| Infant | 4 | 2022 | 1046 | 0.180 |
Why?
|
| Lipase | 1 | 2020 | 18 | 0.180 |
Why?
|
| Phospholipids | 1 | 2021 | 70 | 0.180 |
Why?
|
| Cyclopropanes | 3 | 2021 | 40 | 0.180 |
Why?
|
| Alkynes | 3 | 2021 | 50 | 0.180 |
Why?
|
| Benzoxazines | 3 | 2021 | 46 | 0.180 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 28 | 0.180 |
Why?
|
| Polyneuropathies | 2 | 2012 | 10 | 0.180 |
Why?
|
| Animals | 15 | 2022 | 15081 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2012 | 1369 | 0.160 |
Why?
|
| DNA Damage | 3 | 2016 | 352 | 0.160 |
Why?
|
| Coronary Artery Disease | 2 | 2017 | 142 | 0.160 |
Why?
|
| Oxygen Consumption | 2 | 2017 | 103 | 0.160 |
Why?
|
| NADH Dehydrogenase | 3 | 2011 | 7 | 0.150 |
Why?
|
| Placenta | 3 | 2004 | 97 | 0.150 |
Why?
|
| Microscopy, Electron | 3 | 2004 | 209 | 0.150 |
Why?
|
| Heart | 2 | 2000 | 180 | 0.140 |
Why?
|
| Physical Fitness | 1 | 2017 | 90 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2018 | 1378 | 0.140 |
Why?
|
| Atrophy | 1 | 2016 | 42 | 0.140 |
Why?
|
| Energy Metabolism | 1 | 2017 | 168 | 0.140 |
Why?
|
| Cardiotonic Agents | 1 | 2016 | 37 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 39 | 0.130 |
Why?
|
| Curriculum | 1 | 2018 | 265 | 0.130 |
Why?
|
| Young Adult | 3 | 2021 | 4268 | 0.130 |
Why?
|
| Doxorubicin | 1 | 2016 | 84 | 0.130 |
Why?
|
| Cause of Death | 1 | 2016 | 156 | 0.130 |
Why?
|
| Mortality | 1 | 2016 | 145 | 0.120 |
Why?
|
| Molecular Biology | 1 | 2015 | 46 | 0.120 |
Why?
|
| Lipoproteins, HDL | 1 | 2014 | 46 | 0.120 |
Why?
|
| Lipoproteins, LDL | 1 | 2014 | 62 | 0.120 |
Why?
|
| Epidermis | 1 | 2014 | 24 | 0.120 |
Why?
|
| Infant, Newborn | 2 | 2022 | 894 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 182 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2001 | 803 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 3 | 2011 | 448 | 0.120 |
Why?
|
| Dilatation, Pathologic | 1 | 2013 | 9 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 71 | 0.120 |
Why?
|
| Research | 1 | 2015 | 163 | 0.110 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 885 | 0.110 |
Why?
|
| RNA, Viral | 3 | 2020 | 301 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2017 | 767 | 0.110 |
Why?
|
| Dideoxynucleosides | 1 | 2012 | 11 | 0.110 |
Why?
|
| Succinate Dehydrogenase | 3 | 2001 | 7 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 1995 | 366 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2012 | 22 | 0.110 |
Why?
|
| Obesity | 2 | 2019 | 1067 | 0.110 |
Why?
|
| Drug Combinations | 1 | 2012 | 98 | 0.110 |
Why?
|
| Pyrimidinones | 2 | 2009 | 9 | 0.110 |
Why?
|
| Hippocampus | 1 | 2016 | 561 | 0.110 |
Why?
|
| Botswana | 2 | 2022 | 5 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2012 | 102 | 0.100 |
Why?
|
| DNA Repair | 1 | 1994 | 188 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 227 | 0.100 |
Why?
|
| Pyridines | 1 | 2012 | 116 | 0.100 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2012 | 35 | 0.100 |
Why?
|
| Oxidoreductases | 3 | 2019 | 87 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2021 | 72 | 0.100 |
Why?
|
| Exercise | 1 | 2017 | 613 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2011 | 30 | 0.100 |
Why?
|
| Universities | 1 | 2015 | 442 | 0.100 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2011 | 12 | 0.100 |
Why?
|
| Bone Density | 1 | 2011 | 75 | 0.100 |
Why?
|
| Pathology, Molecular | 1 | 2011 | 9 | 0.100 |
Why?
|
| Viremia | 1 | 2011 | 42 | 0.100 |
Why?
|
| Niacin | 1 | 2010 | 22 | 0.090 |
Why?
|
| Hawaii | 4 | 2020 | 1929 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 97 | 0.090 |
Why?
|
| Vasodilation | 1 | 2010 | 65 | 0.090 |
Why?
|
| Extremities | 1 | 2009 | 18 | 0.090 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 75 | 0.090 |
Why?
|
| F2-Isoprostanes | 1 | 2009 | 20 | 0.090 |
Why?
|
| Vitamin D | 1 | 2011 | 196 | 0.080 |
Why?
|
| Body Fat Distribution | 1 | 2009 | 24 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2009 | 41 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 236 | 0.080 |
Why?
|
| Nevirapine | 2 | 2022 | 7 | 0.080 |
Why?
|
| Risk Factors | 5 | 2017 | 3562 | 0.080 |
Why?
|
| Mice, Knockout | 2 | 2022 | 933 | 0.080 |
Why?
|
| United States | 5 | 2018 | 4223 | 0.080 |
Why?
|
| Embryonic and Fetal Development | 2 | 2001 | 37 | 0.080 |
Why?
|
| Glutathione | 1 | 2009 | 179 | 0.080 |
Why?
|
| Time Factors | 4 | 2018 | 1742 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 628 | 0.080 |
Why?
|
| Prevalence | 2 | 2018 | 1455 | 0.080 |
Why?
|
| Peripheral Nerves | 1 | 2007 | 14 | 0.070 |
Why?
|
| Reactive Oxygen Species | 2 | 2023 | 461 | 0.070 |
Why?
|
| Cattle | 2 | 2002 | 477 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 237 | 0.070 |
Why?
|
| Sensation Disorders | 1 | 2006 | 6 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 974 | 0.070 |
Why?
|
| Alleles | 2 | 2018 | 321 | 0.070 |
Why?
|
| Comorbidity | 3 | 2017 | 623 | 0.070 |
Why?
|
| Lipodystrophy | 1 | 2005 | 8 | 0.070 |
Why?
|
| Proteins | 1 | 2008 | 369 | 0.070 |
Why?
|
| HIV Wasting Syndrome | 1 | 2005 | 8 | 0.070 |
Why?
|
| Glucose Intolerance | 1 | 2005 | 42 | 0.060 |
Why?
|
| Genotype | 2 | 2018 | 730 | 0.060 |
Why?
|
| DNA | 3 | 2019 | 574 | 0.060 |
Why?
|
| Carnitine | 1 | 2004 | 8 | 0.060 |
Why?
|
| Electron Transport Complex II | 2 | 2001 | 7 | 0.060 |
Why?
|
| Electron Transport Complex I | 2 | 2016 | 21 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2021 | 1418 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2016 | 928 | 0.060 |
Why?
|
| Multienzyme Complexes | 2 | 2001 | 69 | 0.060 |
Why?
|
| Phenotype | 2 | 2022 | 689 | 0.060 |
Why?
|
| Thailand | 2 | 2015 | 48 | 0.060 |
Why?
|
| Apoptosis | 1 | 2011 | 1398 | 0.060 |
Why?
|
| Respiration | 1 | 2024 | 58 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2004 | 127 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2004 | 129 | 0.060 |
Why?
|
| Rats | 4 | 2001 | 3483 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2016 | 431 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2005 | 215 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2006 | 753 | 0.060 |
Why?
|
| Heart Rate | 2 | 2017 | 253 | 0.060 |
Why?
|
| Endonucleases | 2 | 1994 | 20 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2003 | 50 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 610 | 0.050 |
Why?
|
| Interleukin-17 | 1 | 2022 | 53 | 0.050 |
Why?
|
| Mice | 3 | 2022 | 5913 | 0.050 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2002 | 25 | 0.050 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2002 | 28 | 0.050 |
Why?
|
| Cell Fractionation | 1 | 2002 | 30 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2014 | 353 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 76 | 0.050 |
Why?
|
| Indicators and Reagents | 1 | 2002 | 58 | 0.050 |
Why?
|
| Aging | 2 | 2017 | 664 | 0.050 |
Why?
|
| Blood Chemical Analysis | 1 | 2001 | 21 | 0.050 |
Why?
|
| Models, Biological | 1 | 2005 | 677 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 1 | 2001 | 60 | 0.050 |
Why?
|
| Myocardium | 1 | 2004 | 235 | 0.050 |
Why?
|
| Microglia | 1 | 2023 | 166 | 0.050 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2021 | 5 | 0.050 |
Why?
|
| Iron | 1 | 2023 | 225 | 0.050 |
Why?
|
| Disease Progression | 1 | 2024 | 601 | 0.050 |
Why?
|
| Oxazines | 1 | 2021 | 26 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 923 | 0.050 |
Why?
|
| Magnesium | 1 | 2002 | 97 | 0.050 |
Why?
|
| Ethanolamines | 1 | 2021 | 12 | 0.050 |
Why?
|
| Risk | 1 | 2021 | 267 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 47 | 0.050 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2021 | 21 | 0.050 |
Why?
|
| Lipogenesis | 1 | 2021 | 18 | 0.050 |
Why?
|
| Phosphatidylethanolamines | 1 | 2021 | 27 | 0.050 |
Why?
|
| Rats, Inbred F344 | 1 | 2001 | 245 | 0.050 |
Why?
|
| Pyridones | 1 | 2021 | 40 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 67 | 0.050 |
Why?
|
| Glycolysis | 1 | 2021 | 68 | 0.050 |
Why?
|
| Kidney | 2 | 2001 | 337 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2021 | 455 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 172 | 0.050 |
Why?
|
| Sarcomeres | 1 | 2000 | 8 | 0.050 |
Why?
|
| Piperazines | 1 | 2021 | 111 | 0.050 |
Why?
|
| CD4-CD8 Ratio | 1 | 2020 | 30 | 0.050 |
Why?
|
| Metabolomics | 1 | 2021 | 81 | 0.050 |
Why?
|
| Incidence | 2 | 2018 | 922 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 448 | 0.050 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2002 | 206 | 0.050 |
Why?
|
| Liver | 2 | 2001 | 479 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 17 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 159 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 61 | 0.040 |
Why?
|
| Mutagens | 1 | 2000 | 69 | 0.040 |
Why?
|
| Brachial Artery | 2 | 2010 | 28 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 157 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2022 | 587 | 0.040 |
Why?
|
| Statistics as Topic | 2 | 2009 | 117 | 0.040 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2000 | 162 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 186 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 68 | 0.040 |
Why?
|
| Base Sequence | 2 | 2003 | 997 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 602 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 643 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2019 | 2026 | 0.040 |
Why?
|
| Animals, Newborn | 2 | 2000 | 343 | 0.040 |
Why?
|
| Homeostasis | 1 | 2019 | 188 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 1609 | 0.040 |
Why?
|
| Feces | 1 | 2017 | 111 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2009 | 171 | 0.040 |
Why?
|
| DNA Polymerase III | 2 | 1994 | 10 | 0.040 |
Why?
|
| Education, Medical | 1 | 2018 | 104 | 0.040 |
Why?
|
| Japan | 1 | 2017 | 305 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2016 | 37 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 93 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2016 | 44 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2017 | 212 | 0.030 |
Why?
|
| Leg | 1 | 2015 | 19 | 0.030 |
Why?
|
| Longevity | 1 | 2017 | 147 | 0.030 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1995 | 22 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1198 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 1995 | 37 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 550 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 136 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2014 | 64 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1995 | 269 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1995 | 81 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 583 | 0.030 |
Why?
|
| Particle Size | 1 | 2014 | 215 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 1994 | 16 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 356 | 0.030 |
Why?
|
| Haplotypes | 1 | 2014 | 182 | 0.030 |
Why?
|
| Oxygen | 1 | 2014 | 207 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2014 | 289 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2014 | 134 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2018 | 1378 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 1033 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 481 | 0.030 |
Why?
|
| Stem Cells | 1 | 1994 | 141 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 143 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 898 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2012 | 107 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 139 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 1180 | 0.030 |
Why?
|
| Age Distribution | 1 | 2012 | 225 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 1568 | 0.020 |
Why?
|
| Arteries | 1 | 2011 | 65 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 400 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 2379 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2011 | 56 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2010 | 60 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1994 | 1518 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 1618 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 149 | 0.020 |
Why?
|
| HIV Protease Inhibitors | 1 | 2008 | 23 | 0.020 |
Why?
|
| Immunoassay | 1 | 2008 | 61 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2012 | 854 | 0.020 |
Why?
|
| Sural Nerve | 1 | 2007 | 4 | 0.020 |
Why?
|
| Neural Conduction | 1 | 2007 | 17 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 935 | 0.020 |
Why?
|
| Neuralgia | 1 | 2007 | 14 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 1354 | 0.020 |
Why?
|
| Diet | 1 | 2012 | 801 | 0.020 |
Why?
|
| Action Potentials | 1 | 2007 | 231 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2005 | 157 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2005 | 304 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 434 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 286 | 0.010 |
Why?
|
| Uncoupling Agents | 1 | 2001 | 3 | 0.010 |
Why?
|
| Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone | 1 | 2001 | 7 | 0.010 |
Why?
|
| Oligomycins | 1 | 2001 | 4 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 2001 | 21 | 0.010 |
Why?
|
| Rotenone | 1 | 2001 | 19 | 0.010 |
Why?
|
| Haplorhini | 1 | 2000 | 22 | 0.010 |
Why?
|
| Cerebellum | 1 | 2000 | 73 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2001 | 421 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 433 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 578 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 1039 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2001 | 1207 | 0.010 |
Why?
|
| Spleen | 1 | 1991 | 199 | 0.010 |
Why?
|
| Kinetics | 1 | 1991 | 708 | 0.010 |
Why?
|